Whether concurrent neoadjuvant hormonal therapy contributes to pCR rates in hormone receptor–positive/HER2-positive breast cancer is being studied in the NRG Oncology/NSABP B-52 trial (NCT02003209)67. Here, NR4A1 is linked to breast carcinoma.